Treatment Strategy for “Non-Responders” to Tadalafil and Vardenafil: A Real-Life Study

Lue, 2004, Summary of the recommendations on sexual dysfunctions in men, J Sex Med, 1, 6, 10.1111/j.1743-6109.2004.10104.x Hatzimouratidis, 2005, A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?, Drugs, 65, 1621, 10.2165/00003495-200565120-00003 Hatzichristou, 2002, Diagnostic steps in the evaluation of patients with erectile dysfunction, J Urol, 168, 615, 10.1016/S0022-5347(05)64690-3 Hatzichristou, 2005, Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders, Eur Urol, 47, 518, 10.1016/j.eururo.2004.12.005 McCullough, 2002, Achieving treatment optimization with sildenafil citrate (Viagra®) in patients with erectile dysfunction, Urology, 60, 28, 10.1016/S0090-4295(02)01688-6 Atiemo, 2003, Salvage of sildenafil failures referred from primary care physicians, J Urol, 170, 2356, 10.1097/01.ju.0000096221.67967.ae Hatzichristou, 2004, The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men, Eur Urol, 45, 634, 10.1016/j.eururo.2004.01.014 Potempa, 2004, Efficacy of vardenafil in men with erectile dysfunction: a flexible-dose community practice study, Eur Urol, 46, 73, 10.1016/j.eururo.2004.03.011 Montorsi, 2004, Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction, Eur Urol, 45, 339, 10.1016/j.eururo.2003.11.010 Skoumal, 2004, Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction, Eur Urol, 46, 362, 10.1016/j.eururo.2004.04.026 McMahon, 2004, Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil, J Sex Med, 1, 292, 10.1111/j.1743-6109.04042.x Mirone, 2005, An evaluation of an alternative dosing regimen with tadalafil, 3times/week, for men with erectile dysfunction: SURE study in 14 European countries, Eur Urol, 47, 846, 10.1016/j.eururo.2005.02.019 Carson, 2004, The ‘effectiveness’ scale—therapeutic outcome of pharmacologic therapies for ED: an international consensus panel report, Int J Impot Res, 16, 207, 10.1038/sj.ijir.3901227 Rutchik, 2001, Practice patterns in the diagnosis and treatment of erectile dysfunction among family practice physicians, Urology, 57, 146, 10.1016/S0090-4295(00)00880-3 Hatzichristou, 2002, Sildenafil citrate: lessons learned from 3 years of clinical experience, Int J Impot Res, 14, S43, 10.1038/sj.ijir.3900805 von Keitz, 2004, A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil, Eur Urol, 45, 499, 10.1016/j.eururo.2003.11.030 Rosano, 2005, Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk, Eur Urol, 47, 214, 10.1016/j.eururo.2004.10.002 Halcox, 2002, The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia, J Am Coll Cardiol, 40, 1232, 10.1016/S0735-1097(02)02139-3 Desouza, 2002, Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes, Diabetes Care, 25, 1336, 10.2337/diacare.25.8.1336 Katz, 2000, Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure, J Am Coll Cardiol, 36, 845, 10.1016/S0735-1097(00)00790-7 Kimura, 2003, PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers, Hypertension, 41, 1106, 10.1161/01.HYP.0000068202.42431.CC Hatzichristou, 2005, Sildenafil failures may be due to inadequate patient instructions and follow-up: A Study on 100 Non-Responders, Eur Urol, 47, 518, 10.1016/j.eururo.2004.12.005 Montorsi, 2006, Can phosphodiesterase type 5 inhibitors cure erectile dysfunction?, Eur Urol, 49, 979, 10.1016/j.eururo.2005.12.055